ProQR Therapeutics (PRQR) Cash from Investing Activities (2013 - 2026)

ProQR Therapeutics has reported Cash from Investing Activities for 14 years, with the latest figure at -$192002.3 in Q1 2026.

• Quarterly Cash from Investing Activities rose 18.51% year-over-year to -$192002.3 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.1 million (down 107.51% YoY) and the FY2025 annual result came in at -$1.2 million, up 72.72% from the prior year.
• Cash from Investing Activities rose to -$192002.3 in Q1 2026 per PRQR's latest filing, from -$612286.9 in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $18.4 million in Q3 2024 and troughed at -$19.3 million in Q1 2024.
• A 5-year average of -$98841.4 and a median of -$246490.1 in 2022 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities soared 27652.3% in 2023, then sank 20065.27% in 2024.
• Over 5 years, Cash from Investing Activities stood at $19384.7 in 2022, then jumped by 27652.3% to $5.4 million in 2023, then slumped by 155.38% to -$3.0 million in 2024, then surged by 79.45% to -$612286.9 in 2025, then soared by 68.64% to -$192002.3 in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$192002.3, -$612286.9, and -$197570.3 for Q1 2026, Q4 2025, and Q3 2025 respectively.